GlassScriptPhysician profile
Cameron Joel Harper
NPI 1497364954
$6,460.22
in general payments reported to CMS, 2019-2025
43 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $862 · 2022: $736 · 2023: $1,600 · 2024: $1,786 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,851 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,851.03 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $941.70 | 2021-2025 | Evenity, Repatha, Otezla |
| Corcept Therapeutics | $551.70 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $510.78 | 2021-2025 | |
| Novo Nordisk INC | $449.56 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $449.53 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $412.57 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $358.11 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $327.88 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.70 | 2021-2025 | Jardiance, Ofev |
| Radius Health, INC. | $261.35 | 2021-2025 | Tymlos |
| Sumitomo Pharma America, INC. | $193.04 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $185.39 | 2022-2025 | |
| Pfizer INC. | $153.78 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $132.54 | 2023-2024 | Rexulti |
| Eisai INC. | $131.12 | 2021-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $113.40 | 2024 | Rebyota |
| Amarin Pharma, INC. | $103.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $96.06 | 2021-2023 | |
| Esperion Therapeutics, INC. | $72.98 | 2021-2025 | Nexletol |
| Sanofi Pasteur INC. | $67.19 | 2025 | |
| Medtronic, INC. | $63.45 | 2023 | Inpen Smart Insulin Delivery System |
| Baxter Healthcare | $58.00 | 2023 | Hillrom - Eli280 Cardiograph |
| Exact Sciences Corporation | $50.78 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $47.96 | 2023 | Rexulti, Vyepti |
| Nestle Healthcare Nutrition INC. | $42.86 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.22 | 2023-2025 | Xifaxan, Trulance |
| Edwards Lifesciences Corporation | $32.81 | 2025 | Sapien 3 Ultra Resilia |
| Daiichi Sankyo INC. | $31.05 | 2021-2022 | |
| Averitas Pharma INC. | $25.66 | 2025 | Qutenza |
| Fresenius Kabi USA, LLC | $25.26 | 2025 | |
| Boston Scientific Corporation | $23.61 | 2024 | |
| Abiomed | $23.45 | 2024 | Impella |
| Astellas Pharma US INC | $22.82 | 2023 | Veozah |
| Insulet Corporation | $22.34 | 2023 | Omnipod |
| Echosens North America, INC. | $20.46 | 2025 | Fibroscan |
| Abbott Laboratories | $19.90 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $19.88 | 2023 | Verquvo, Belsomra, Steglatro |
| Amryt Pharma Holdings LTD | $17.91 | 2021 | |
| Athena Bioscience, LLC | $17.77 | 2024 | Qdolo |
| Xeris Pharmaceuticals, INC. | $16.85 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.50 | 2023 | Glassia |
| Mylan Specialty L.P. | $15.92 | 2021 | |
| Currax Pharmaceuticals LLC | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.